ArticleExperimental and therapeutic medicine2021
Regulatory effect of mitoQ on the mtROS-NLRP3 inflammasome pathway in leptin-pretreated BEAS-2 cells.
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Lack of association between leptin concentrations and cystic fibrosis: A meta-analysis and regression.Frontiers in endocrinology · 2023Pooled it
- Role of Leptin as a Link between Asthma and Obesity: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Obesity: Next game changer of allergic airway diseases?Clinical and translational medicine · 2025Review
- Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.American journal of respiratory and critical care medicine · 2024Review
- Weight Loss Interventions for Adults With Obesity-Related Asthma.The journal of allergy and clinical immunology. In practice · 2024Article
- Mitochondrial Dysfunction and Metabolic Reprogramming in Obesity and Asthma.International journal of molecular sciences · 2024Review
- Gaps and Future Directions in Clinical Research on Obesity-Related Asthma.Pulmonary therapy · 2023Review
- Diet-induced obesity worsens allergen-induced type 2/type 17 inflammation in airways by enhancing DUOX1 activation.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Herbal medicine for the treatment of obesity-associated asthma: a comprehensive review.Frontiers in pharmacology · 2023Review
- DEK deficiency suppresses mitophagy to protect against house dust mite-induced asthma.Frontiers in immunology · 2023Article
- Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obese asthma is a phenotype of asthma whose occurrence is gradually increasing in both adults and children. The majority of studies have demonstrated that obesity is a major risk factor for asthma and the effect of obesity on the lungs is considerable. NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome has been previously demonstrated to serve a role in obese asthma mediated by mitochondrial reactive oxygen species (mtROS). The aim of the present
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.